Literature DB >> 22321380

Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro.

Jie Li1, Donglan Zhang, Kathleen M Ward, George C Prendergast, Iraimoudi S Ayene.   

Abstract

Cell viability assays have a variety of well known practical and technical limitations. All the available approaches have disadvantages, such as non-linearity, high background and cumbersome protocols. Several commonly used tetrazolium chemicals rely upon generation of a colored formazan product formed by mitochondrial reduction of these compounds via phenazine methosulfate (PMS). However, sensitivity is inherently limited because their reduction relies on mitochondrial bioreduction and cellular transport of PMS, as well as accessibility to tetrazolium chemicals. In this study, we identify hydroxethyldisulfide (HEDS) as an inexpensive probe that can measure cellular metabolic activity without the need of PMS. In tissue culture medium, HEDS accurately quantitated metabolically active live cells in a linear manner superior to tetrazolium based and other assays. Cell toxicity produced by chemotherapeutics (cisplatin, etoposide), oxidants (hydrogen peroxide, acetaminophen), toxins (phenyl arsine oxide, arsenite) or ionizing radiation was rapidly determined by the HEDS assay. We found that HEDS was superior to other commonly used assays for cell viability determinations in its solubility, membrane permeability, and intracellular conversion to a metabolic reporter that is readily transported into the extracellular medium. Our findings establish the use of HEDS in a simple, rapid and low cost assay to accurately quantify viable cells.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22321380      PMCID: PMC3327773          DOI: 10.1016/j.tiv.2012.01.007

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  46 in total

1.  Oxidation of cellular thiols by hydroxyethyldisulphide inhibits DNA double-strand-break rejoining in G6PD deficient mammalian cells.

Authors:  I S Ayene; C J Koch; S W Tuttle; T D Stamato; M L Perez; J E Biaglow
Journal:  Int J Radiat Biol       Date:  2000-11       Impact factor: 2.694

2.  The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines.

Authors:  E U Kurz; S E Wilson; K B Leader; B P Sampey; W P Allan; J C Yalowich; D J Kroll
Journal:  Mol Cancer Ther       Date:  2001-12       Impact factor: 6.261

3.  Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi.

Authors:  C J Henderson; C R Wolf; N Kitteringham; H Powell; D Otto; B K Park
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

4.  Mutation in the glucose-6-phosphate dehydrogenase gene leads to inactivation of Ku DNA end binding during oxidative stress.

Authors:  Iraimoudi S Ayene; Thomas D Stamato; Stanley K Mauldin; John E Biaglow; Steven W Tuttle; Susan F Jenkins; Cameron J Koch
Journal:  J Biol Chem       Date:  2002-01-11       Impact factor: 5.157

5.  G6PD deficient cells and the bioreduction of disulfides: effects of DHEA, GSH depletion and phenylarsine oxide.

Authors:  J E Biaglow; I S Ayene; C J Koch; J Donahue; T D Stamato; S W Tuttle
Journal:  Biochem Biophys Res Commun       Date:  2000-07-14       Impact factor: 3.575

Review 6.  Cisplatin: a review of toxicities and therapeutic applications.

Authors:  K Barabas; R Milner; D Lurie; C Adin
Journal:  Vet Comp Oncol       Date:  2008-03       Impact factor: 2.613

7.  Radiation response of cells during altered protein thiol redox.

Authors:  John E Biaglow; Iraimoudi S Ayene; Cameron J Koch; Jeremiah Donahue; Thomas D Stamato; John J Mieyal; Stephen W Tuttle
Journal:  Radiat Res       Date:  2003-04       Impact factor: 2.841

8.  Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

Authors:  Muthu Selvakumaran; Debra A Pisarcik; Rudi Bao; Anthony T Yeung; Thomas C Hamilton
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

9.  Uses and limitations of the XTT assay in studies of Candida growth and metabolism.

Authors:  D M Kuhn; M Balkis; J Chandra; P K Mukherjee; M A Ghannoum
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

10.  Development of an XTT tetrazolium salt-based assay for detection of specific hyperthermia sensitizers in a high-flux screening programme.

Authors:  S Lechpammer; A Asea; R Mallick; R Zhong; M Y Sherman; S K Calderwood
Journal:  Int J Hyperthermia       Date:  2002 May-Jun       Impact factor: 3.914

View more
  7 in total

1.  Real-time cell analysis: sensitivity of different vertebrate cell cultures to copper sulfate measured by xCELLigence(®).

Authors:  S Rakers; F Imse; M Gebert
Journal:  Ecotoxicology       Date:  2014-07-08       Impact factor: 2.823

2.  A bioactive probe of the oxidative pentose phosphate cycle: novel strategy to reverse radioresistance in glucose deprived human colon cancer cells.

Authors:  Jie Li; Kathleen M Ward; Donglan Zhang; Eswarkumar Dayanandam; Albert S Denittis; George C Prendergast; Iraimoudi S Ayene
Journal:  Toxicol In Vitro       Date:  2012-08-16       Impact factor: 3.500

3.  A bioactive probe for glutathione-dependent antioxidant capacity in breast cancer patients: implications in measuring biological effects of arsenic compounds.

Authors:  Jie Li; Donglan Zhang; Pearl A Jefferson; Kathleen M Ward; Iraimoudi S Ayene
Journal:  J Pharmacol Toxicol Methods       Date:  2013-10-20       Impact factor: 1.950

4.  Berberine activates AMPK to suppress proteolytic processing, nuclear translocation and target DNA binding of SREBP-1c in 3T3-L1 adipocytes.

Authors:  Jaewoong Jang; Yoonju Jung; Seong Jun Seo; Seok-Min Kim; Yae Jie Shim; Soo Hyun Cho; Sang-In Chung; Yoosik Yoon
Journal:  Mol Med Rep       Date:  2017-04-26       Impact factor: 2.952

5.  Comparison of specific expression profile in two in vitro hypoxia models.

Authors:  Geovana Calvo-Anguiano; Jose J Lugo-Trampe; Alberto Camacho; Salvador Said-Fernández; Roberto Mercado-Hernández; Viviana Zomosa-Signoret; Augusto Rojas-Martínez; Rocio Ortiz-López
Journal:  Exp Ther Med       Date:  2018-04-10       Impact factor: 2.447

6.  Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancer.

Authors:  James DuHadaway; George C Prendergast
Journal:  Oncotarget       Date:  2016-02-16

7.  A calpain inhibitor protects against fractalkine production in lipopolysaccharide-treated endothelial cells.

Authors:  Jaewoong Jang; Yoosik Yoon; Dong-Jin Oh
Journal:  Kidney Res Clin Pract       Date:  2017-09-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.